ArticleACS infectious diseases2020
Tight-Binding Hydroxypyrazole HIV-1 Nef Inhibitors Suppress Viral Replication in Donor Mononuclear Cells and Reverse Nef-Mediated MHC-I Downregulation.
Open access · greenAbstract read
In one paragraph
Article in ACS infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Nef as a driver of immunodeficiency and HIV-associated diseases: insights from mouse models.Frontiers in immunology · 2026Review
- Multifaceted Role of Nef in HIV-Associated Neurocognitive Disorder: Histopathological Alterations and Underlying Mechanisms.Brain sciences · 2025Review
- Nef defect attenuates HIV viremia and immune dysregulation in the bone marrow-liver-thymus-spleen (BLTS) humanized mouse model.Virology · 2024Article
- PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication.Cell chemical biology · 2024Article
- Neutron Reflectometry and Molecular Simulations Demonstrate HIV-1 Nef Homodimer Formation on Model Lipid Bilayers.Journal of molecular biology · 2023Article
- The Persistence of HIV Diversity, Transcription, and Nef Protein in Kaposi's Sarcoma Tumors during Antiretroviral Therapy.Viruses · 2022Article
- The HIV-1 protein Nef activates the Tec family kinase Btk by stabilizing an intermolecular SH3-SH2 domain interaction.Science signaling · 2022Article
- Review
- Regenerable and high-throughput surface plasmon resonance assay for rapid screening of anti-SARS-CoV-2 antibody in serum samples.Analytica chimica acta · 2022Article
- The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells.The Journal of clinical investigation · 2022Article
- Inhibitors of HIV-1 Nef-Mediated Activation of the Myeloid Src-Family Kinase Hck Block HIV-1 Replication in Macrophages and Disrupt MHC-I Downregulation.ACS infectious diseases · 2022Article
- Direct interaction between ABCA1 and HIV-1 Nef: Molecular modeling and virtual screening for inhibitors.Computational and structural biotechnology journal · 2021Article
- Nef homodimers down-regulate SERINC5 by AP-2-mediated endocytosis to promote HIV-1 infectivity.The Journal of biological chemistry · 2020Article
- Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.The Journal of biological chemistry · 2020Review
- HIV-1 Nef dimers short-circuit immune receptor signaling by activating Tec-family kinases at the host cell membrane.The Journal of biological chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Haibin ShiDepartment of Microbiology and Molecular Genetics , University of Pittsburgh School of Medicine , Suite 523 Bridgeside Point II, 450 Technology Drive , Pittsburgh , Pennsylvania 15219 , United States.
Colin M TiceFox Chase Chemical Diversity Center, Inc. , Pennsylvania Biotechnology Center , 3805 Old Easton Road , Doylestown , Pennsylvania 18902 , United States.ORCID 0000-0002-9918-7383
Lori Emert-SedlakDepartment of Microbiology and Molecular Genetics , University of Pittsburgh School of Medicine , Suite 523 Bridgeside Point II, 450 Technology Drive , Pittsburgh , Pennsylvania 15219 , United States.
Li ChenDepartment of Microbiology and Molecular Genetics , University of Pittsburgh School of Medicine , Suite 523 Bridgeside Point II, 450 Technology Drive , Pittsburgh , Pennsylvania 15219 , United States.
Wing Fai LiDepartment of Microbiology and Molecular Genetics , University of Pittsburgh School of Medicine , Suite 523 Bridgeside Point II, 450 Technology Drive , Pittsburgh , Pennsylvania 15219 , United States.
Marianne CarlsenFox Chase Chemical Diversity Center, Inc. , Pennsylvania Biotechnology Center , 3805 Old Easton Road , Doylestown , Pennsylvania 18902 , United States.ORCID 0000-0003-2178-8047
Jay E WrobelFox Chase Chemical Diversity Center, Inc. , Pennsylvania Biotechnology Center , 3805 Old Easton Road , Doylestown , Pennsylvania 18902 , United States.ORCID 0000-0002-7410-5134
Allen B ReitzFox Chase Chemical Diversity Center, Inc. , Pennsylvania Biotechnology Center , 3805 Old Easton Road , Doylestown , Pennsylvania 18902 , United States.ORCID 0000-0003-2780-4044
Thomas E SmithgallDepartment of Microbiology and Molecular Genetics , University of Pittsburgh School of Medicine , Suite 523 Bridgeside Point II, 450 Technology Drive , Pittsburgh , Pennsylvania 15219 , United States.ORCID 0000-0001-5238-3806
University of Pittsburgh · USFox Chase Chemical Diversity Center · US
Funding
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1MSmall Molecule Inhibitors of HIV Nef SignalingR01AI057083 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SMITHGALL, THOMAS E. · 2003 to 2019
$5.1MChemical Biology of HIV-1 NefR01AI152677 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas E. Smithgall · 2020 to 2026
$4.8MSmall Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDSR42GM112516 · NIGMS · FOX CHASE CHEMICAL DIVERSITY CENTER, INC · PI SMITHGALL, THOMAS E. · 2016 to 2017
$2.0MSmall Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDSR41GM112516 · NIGMS · FOX CHASE CHEMICAL DIVERSITY CENTER, INC · PI SMITHGALL, THOMAS E. · 2014 to 2014
$225kNIAID NIH HHS R01 AI057083NIAID NIH HHS R01 AI152677NIAID NIH HHS UM1 AI126617NIGMS NIH HHS R41 GM112516NIGMS NIH HHS R42 GM112516
Abstract
The HIV-1 Nef accessory factor is critical to the viral life cycle
Indexed as
Anti-Retroviral AgentsCell LineDown-RegulationDrug DevelopmentHistocompatibility Antigens Class IHIV-1HumansInhibitory Concentration 50Leukocytes, Mononuclearnef Gene Products, Human Immunodeficiency VirusPyrazolesTissue DonorsVirus ReplicationAnti-Retroviral AgentsHistocompatibility Antigens Class Inef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1Pyrazolesantiretroviral drug developmentHIV-1 Nef inhibitorsHIV accessory proteinsHIV/AIDSsurface plasmon resonance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.